gms | German Medical Science

45. Kongress der Deutschen Gesellschaft für Rheumatologie, 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie, 27. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie

06.09. - 09.09.2017, Stuttgart

CSF-1 and IL-34: Distinct Potential Biomarkers for Lupus

Meeting Abstract

  • Julia Weinmann-Menke - Universitätsmedizin der Johannes Gutenberg-Universität Mainz, I. Medizinische Klinik, Schwerpunkt für Rheumatologie, klinische Immunologie und Nephrologie, Mainz
  • Myriam Meineck - Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz
  • Arndt Weinmann - Universitätsklinikum Mainz, I. Medizinische Klinik und Poliklinik, Mainz
  • Andreas Schwarting - Universitätsklinikum Mainz und ACURA Rheumazentrum Rheinland-Pfalz AG, Bad Kreuznach

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. 45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR). Stuttgart, 06.-09.09.2017. Düsseldorf: German Medical Science GMS Publishing House; 2017. DocVK.21

doi: 10.3205/17dgrh231, urn:nbn:de:0183-17dgrh2315

Veröffentlicht: 4. September 2017

© 2017 Weinmann-Menke et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Background: A noninvasive means to predict the onset and recurrence of lupus is needed to optimize and individualize treatment. Macrophages (Mø) are prominent in inflamed tissues targeted for destruction in SLE. We hypothesized that the principal molecules required for Mø survival and proliferation are biomarkers for SLE. CSF-1 and IL-34 are promising candidates as both (i) bind to cFMS expressed by Mø, thereby promoting Mø survival and proliferation and (ii) mediate lupus. However, IL-34 and CSF-1 have differing functions, which may be related to IL-34, not CSF-1, binding to a second receptor and distinct spatial temporal expression.

Methods: We analyzed serum and urine CSF-1 and IL-34 levels in SLE patients with nephritis (LN), arthritis (LA), cutaneous and serositis compared with healthy controls in two large cohorts (ELISA). While serum and urine CSF-1 expression is elevated in each manifestation, CSF-1 is notably higher in LN. In contrast, serum IL-34 expression is dramatically higher in LA, not LN. Thus, we probed for CSF-1 and IL-34 expression in LN (kidney) and LA (synovium). Moreover, we longitudinally tracked serum CSF-1 and IL-34 prior to LN (biopsy proven), with disease activity including flares and during LA in comparison to disease activity.

Results: 1. LN. CSF-1 and IL-34 are expressed in the same and different renal tubular epithelial cells in LN. Elevated serum or urine CSF-1, not IL-34, levels correlate with increasing intra-renal CSF-1 expression and histopathology index. Longitudinally tracking serum CSF-1, not IL-34, levels heralds the initial onset of nephritis and a rise in serum or urine CSF-1 predicts LN recurrences before clinical evidence of renal dysfunction and conventional serologic measures. 2. LA. IL-34, not CSF-1, expression is higher in synovial fluid and synovium in LA compared to osteoarthritis and healthy controls and correlates with magnitude of intra-synovial leukocytes. Moreover, intra-synovial IL-34 expression is similar in LA and rheumatoid arthritis. Longitudinally monitoring serum IL-34, not CSF-1, levels track with clinical disease activity in LA and RA.

Conclusion: Serial monitoring a rise in serum or urine CSF-1, not IL-34, in SLE reflects kidney histopathology and renal disease activity and the onset and reoccurrences of LN more accurately than conventional laboratory measures. While serial monitoring a rise in serum IL-34, not CSF-1, reflects clinical disease activity in LA. Thus, CSF-1 and IL-34 are inexpensive and accurate potential biomarkers for LN and LA, respectively.